Our results indicate that the simultaneous inhibition of RAD52-mediated DNA repair with the induction of DSBs appears to exaggerate the cytotoxicity of mitoxantrone and doxorubicin in BRCA1-deficient cancer cell lines. This evidence concerns the gene RAD52 and cancer.